epirubicin - Robuta Search

https://pubchem.ncbi.nlm.nih.gov/bioassay/1208095 AID 1208095 - Excretory balance of radioactivity in bile following intravenous 14C-epirubicin at 1... BioAssay record AID 1208095 submitted by ChEMBL: Excretory balance of radioactivity in bile following intravenous 14C-epirubicin at 1 mg.Kg-1 dose in rat. https://pubchem.ncbi.nlm.nih.gov/bioassay/1208181 AID 1208181 - Plasma clearance of epirubicin following intravenous epirubicin solution at 1 mg.Kg-1... BioAssay record AID 1208181 submitted by ChEMBL: Plasma clearance of epirubicin following intravenous epirubicin solution at 1 mg.Kg-1 dose in rabbit. https://theses.gla.ac.uk/3956/ The influence of hepatic function on the pharmacokinetics and dose requirements of epirubicin -... the influence hepatic function https://pubchem.ncbi.nlm.nih.gov/bioassay/1207941 AID 1207941 - Urinary excretion of epirubicin following epirubicin at 50 mg.m-2 dose in cancer... BioAssay record AID 1207941 submitted by ChEMBL: Urinary excretion of epirubicin following epirubicin at 50 mg.m-2 dose in cancer patients. https://adisinsight.springer.com/drugsafety/803175117?error=cookies_not_supported&code=a36a8e8f-a74f-46df-9cb7-d0ce5bb38717 Cisplatin/epirubicin/fluorouracil - AdisInsight A 41-year-old man developed nausea and vomiting while receiving cisplatin, epirubicin and fluorouracil. Subsequently, he died. The man, who had been diagnosed cisplatin epirubicin fluorouracil adisinsight https://pubmed.ncbi.nlm.nih.gov/7577476/ Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with... Sixty-four consecutive patients with locally advanced (n = 7) or metastatic breast cancer (n = 57), were treated with a combination of laevofolinic acid 100 mg... acid fluorouracil cyclophosphamide https://research.birmingham.ac.uk/en/projects/neo-tango-a-neoadjuvant-study-of-sequential-epirubicincyclophosha/ Neo-Tango: A Neoadjuvant Study of Sequential Epirubicin+Cyclophoshamide & Paclitaxel Gemcitabine in... neo tango https://pubchem.ncbi.nlm.nih.gov/bioassay/1207834 AID 1207834 - Recovery of epirubicinol-glucuronide following intraperitoneal epirubicin at 4... BioAssay record AID 1207834 submitted by ChEMBL: Recovery of epirubicinol-glucuronide following intraperitoneal epirubicin at 4 mg.Kg-1 dose in mouse. aid recovery https://pubmed.ncbi.nlm.nih.gov/25637379/ A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on... The tolerability rate of a dose-density regimen with FEC followed by weekly paclitaxel was considered not promising for completing the accrual of this study. https://pubchem.ncbi.nlm.nih.gov/bioassay/1207938 AID 1207938 - Urinary excretion of epirubicin glucuronide following epirubicin at 60-150 mg.m-2... BioAssay record AID 1207938 submitted by ChEMBL: Urinary excretion of epirubicin glucuronide following epirubicin at 60-150 mg.m-2 dose in cancer patients. https://adisinsight.springer.com/drugsafety/803116973?error=cookies_not_supported&code=f3dd8d96-2b57-4fbe-bef2-52cca03b0c59 Cyclophosphamide/epirubicin/fluorouracil - AdisInsight A retrospective study identified a patient [age and sex not stated] who developed oral mucositis after administration of epirubicin [Farmorubicin], fluorouracil cyclophosphamide epirubicin fluorouracil adisinsight https://pubchem.ncbi.nlm.nih.gov/bioassay/1208010 AID 1208010 - Initial phase half-life of epirubicin following intravenous epirubicin at 40-60... BioAssay record AID 1208010 submitted by ChEMBL: Initial phase half-life of epirubicin following intravenous epirubicin at 40-60 mg.m-2 dose in cancer patients. https://researchconnect.buffalo.edu/en/publications/a-uridine-glucuronosyltransferase-2b7-polymorphism-predicts-epiru/ A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in... uridine polymorphism https://pubchem.ncbi.nlm.nih.gov/bioassay/1207883 AID 1207883 - Binding of 14C-epirubicin at 1000 ng.ml-1 concentration to plasma protein of mouse -... BioAssay record AID 1207883 submitted by ChEMBL: Binding of 14C-epirubicin at 1000 ng.ml-1 concentration to plasma protein of mouse. https://pubmed.ncbi.nlm.nih.gov/8629032/?dopt=Abstract Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary... Attempting to develop a new active, convenient regimen, we initiated a phase I study of paclitaxel (Taxol; Bristol-Myers squibb Company, Princeton, NJ)... https://pubchem.ncbi.nlm.nih.gov/bioassay/1208108 AID 1208108 - Excretory balance of radioactivity in urine following intravenous 14C-epirubicin at 1... BioAssay record AID 1208108 submitted by ChEMBL: Excretory balance of radioactivity in urine following intravenous 14C-epirubicin at 1 mg.Kg-1 dose in rat. https://pubchem.ncbi.nlm.nih.gov/bioassay/1207936 AID 1207936 - Urinary excretion of epirubicin following epirubicin at 60-150 mg.m-2 dose in cancer... BioAssay record AID 1207936 submitted by ChEMBL: Urinary excretion of epirubicin following epirubicin at 60-150 mg.m-2 dose in cancer patients. https://digital.library.adelaide.edu.au/items/d8ee7518-03f3-468c-b065-bd68b9148120 Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and... Purpose: Most adjuvant breast cancer treatment regimens include the combination of an anthracycline (epirubicin or doxorubicin) and the alkylating agent... breast cancer treatment pharmacogenetics adjuvant cyclophosphamide epirubicin https://pubchem.ncbi.nlm.nih.gov/bioassay/1208022 AID 1208022 - Initial phase half-life of epirubicin following intravenous epirubicin at 90-150... BioAssay record AID 1208022 submitted by ChEMBL: Initial phase half-life of epirubicin following intravenous epirubicin at 90-150 mg.m-2 dose in cancer... https://pubchem.ncbi.nlm.nih.gov/bioassay/1208004 AID 1208004 - Terminal elimination of metabolite of epirubicin following intravenous epirubicin at... BioAssay record AID 1208004 submitted by ChEMBL: Terminal elimination of metabolite of epirubicin following intravenous epirubicin at 40-135 mg.m-2 dose in... aid terminal elimination metabolite epirubicin https://scholars.duke.edu/publication/1405542 Scholars@Duke publication: Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle... scholars duke publication tailored epirubicin https://pubmed.ncbi.nlm.nih.gov/9400950/ Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in... A multicentric, prospective phase III study was carried out with the aim of testing the so-called 'worst drug rule' hypothesis, which suggests the use of an... https://pubchem.ncbi.nlm.nih.gov/bioassay/1207945 AID 1207945 - Cumulative urinary excretion of epirubicin and its metabolites following epirubicin... BioAssay record AID 1207945 submitted by ChEMBL: Cumulative urinary excretion of epirubicin and its metabolites following epirubicin at 50 mg.m-2 dose in... aid cumulative urinary excretion https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-bortezomib-with-epirubicin-carboplatin-and-capecitabine-chemotherapy-for-cancer-where-the-food-pipe-meets-the-stomach A trial of bortezomib with epirubicin, carboplatin and capecitabine chemotherapy for cancer where... This trial looked at the drug bortezomib with chemotherapy for cancer that started where the food pipe (oesophagus) meets the stomach.